MedTrace Logo

Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

NCT00144833 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2007-11-12

No results posted yet for this study

Summary

For HIV-infected individuals with highly resistant viruses, higher drug levels may be required to block the virus. This study investigates that concept by comparing the efficacy of standard fosamprenavir/ritonavir to an increased dose of boosted fosamprenavir and to a combination of fosamprenavir (increased dose)/lopinavir/ritonavir.

Conditions

Interventions

DRUG

fosamprenavir/ritonavir (700mg/100mg BID)

DRUG

fosamprenavir/ritonavir (1400mg/100mg BID)

DRUG

fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, MD · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31

Countries

  • Australia
  • Belgium
  • Canada
  • France
  • Germany
  • Greece
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144833 on ClinicalTrials.gov